Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18629406 | METHOD AND KIT FOR BOWEL PREPARATION | April 2024 | April 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18612888 | CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | March 2024 | May 2025 | Allow | 14 | 0 | 0 | Yes | No |
| 18587736 | EMBOLIC COMPOSITIONS | February 2024 | April 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18582320 | PHARMACEUTICAL COMPOSITIONS OF DIMETHYL FUMARATE | February 2024 | June 2025 | Allow | 16 | 1 | 1 | No | No |
| 18529962 | NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS | December 2023 | August 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18480331 | MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY | October 2023 | October 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18244391 | INTRANASAL DELIVERY OF CANNABIDIOL TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | September 2023 | November 2024 | Abandon | 14 | 2 | 0 | No | Yes |
| 18455930 | METHOD FOR BOWEL PREPARATION | August 2023 | October 2024 | Allow | 13 | 2 | 0 | No | No |
| 18225475 | FORMULATIONS COMPRISING CYCLOSPORIN A | July 2023 | October 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18223252 | THERAPEUTIC CLAY COMPOSITIONS AND METHODS OF USING | July 2023 | July 2024 | Allow | 12 | 1 | 0 | No | No |
| 18345643 | COMPOSITIONS AND METHODS RELATED TO RHAMNUS PRINOIDES (GESHO) EXTRACT FOR THE INHIBITION OF POLYMICROBIAL BIOFILM FORMATION | June 2023 | April 2025 | Allow | 22 | 2 | 0 | Yes | No |
| 18332487 | LIPID NANOPARTICLE FORMULATIONS | June 2023 | December 2024 | Allow | 18 | 1 | 1 | No | No |
| 18306402 | PERSONAL CARE PRODUCTS COMPRISING HIGHLY CATIONIC SUBSTITUTED STARCHES | April 2023 | May 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18188780 | DOSING WITH AN AZOLOPYRIMIDINE COMPOUND | March 2023 | May 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18187132 | ANTIMICROBIAL TOPICAL COMPOSITIONS CONTAINING MANUKA OIL | March 2023 | October 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18185175 | TRANSDERMAL PATCH | March 2023 | April 2024 | Abandon | 13 | 0 | 1 | No | No |
| 18115890 | Methods of Making Capsules | March 2023 | June 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18167123 | FORMULATIONS, METHODS, KITS, AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | February 2023 | March 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18100363 | NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS | January 2023 | September 2023 | Allow | 7 | 0 | 0 | Yes | No |
| 18089861 | PAINTING WITH BIOCIDES COMPOSITION AND/OR PROLONGED RELEASE PESTICIDES | December 2022 | May 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18007705 | KINASE INHIBITORS | December 2022 | June 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18056771 | INJECTABLE AND INHALABLE FORMULATIONS | November 2022 | April 2025 | Allow | 29 | 4 | 0 | Yes | No |
| 17988890 | PHOTOSTABILIZING COMPOUNDS, COMPOSITIONS, AND METHODS | November 2022 | July 2023 | Allow | 8 | 0 | 0 | Yes | No |
| 17966668 | INJECTABLE SLURRIES AND METHODS OF MANUFACTURING THE SAME | October 2022 | September 2023 | Allow | 11 | 0 | 0 | No | No |
| 17915952 | Method for Treating SARS and Treating or Preventing ARDS | September 2022 | May 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17896808 | LEVODOPA FRACTIONATED DOSE COMPOSITION AND USE | August 2022 | August 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 17893716 | MANUFACTURING METHOD OF HEMOSTATIC MATERIAL AND HEMOSTATIC MATERIAL PREPARED THEREBY | August 2022 | February 2025 | Abandon | 29 | 2 | 0 | No | No |
| 17870313 | LIPID COMPOUND AS WELL AS LIPID CARRIER, NUCLEIC ACID LIPID NANOPARTICLE COMPOSITION AND PHARMACEUTICAL PREPARATION CONTAINING SAME | July 2022 | March 2023 | Allow | 8 | 1 | 1 | No | No |
| 17864332 | COMPOSITION AS AUXILIARY MEANS FOR ORAL MEDICATION | July 2022 | March 2024 | Allow | 21 | 1 | 0 | No | No |
| 17849887 | METHOD AND KIT FOR BOWEL PREPARATION | June 2022 | January 2024 | Allow | 18 | 2 | 0 | No | No |
| 17808649 | HETEROCYCLIC COMPOUNDS AND NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING SAME | June 2022 | November 2023 | Abandon | 17 | 2 | 0 | No | No |
| 17784555 | PHOSPHATE-CONTAINING ANTI-CORROSIVE PIGMENT | June 2022 | June 2025 | Allow | 36 | 0 | 0 | No | No |
| 17832997 | SYSTEM AND METHOD FOR THERAPEUTIC COMPOSITIONS FROM A PLURALITY OF DIFFERENT BIRTH TISSUES AND EXOSOMES | June 2022 | October 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17782425 | PHARMACEUTICAL COMPOSITION COMPRISING ELTROMBOPAG BIS(MONOETHANOLAMINE) | June 2022 | May 2025 | Allow | 35 | 1 | 0 | No | No |
| 17824654 | METHOD OF TREATMENT | May 2022 | March 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17750970 | PHOTOCHEMICALLY STABLE, NON-LEACHING, BRIDGED POLYSILSESQUIOXANE BASED SUNSCREENS | May 2022 | March 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17744534 | SYSTEMS AND METHODS FOR PREPARING AND TRANSPORTING AN INJECTABLE SLURRY | May 2022 | July 2023 | Abandon | 14 | 1 | 0 | No | No |
| 17658288 | Personal Care Compositions for Treating Odor Causing Bacteria and Methods for the Same | April 2022 | September 2024 | Allow | 30 | 4 | 1 | Yes | No |
| 17653575 | PROCESS FOR THE MANUFACTURE AND USE OF PANCREATIN MICROPELLET CORES | March 2022 | March 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17753307 | Composition and Method for treatment of diabetes | February 2022 | February 2025 | Allow | 36 | 0 | 0 | No | No |
| 17621778 | Oral Care Compositions Comprising Star-Shaped Polymers | December 2021 | November 2024 | Allow | 35 | 0 | 0 | No | No |
| 17551550 | Pharmaceutical Compositions of Dimethyl Fumarate | December 2021 | January 2024 | Allow | 25 | 1 | 1 | No | No |
| 17616074 | A POLYMER AND A TOPICAL COMPOSITION COMPRISING THE POLYMER | December 2021 | August 2024 | Allow | 33 | 0 | 0 | No | No |
| 17535080 | CARBON MONOXIDE-BASED THERAPIES AND IMPLANTABLE DEVICES FOR THE TREATMENT OF VASCULAR DISEASE | November 2021 | March 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17535493 | INJECTABLE SLURRIES AND METHODS OF MANUFACTURING THE SAME | November 2021 | May 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17612468 | TREATMENT OF SYSTOLIC DYSFUNCTION | November 2021 | January 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17610175 | BIOACTIVE GLASS COMPOSITIONS | November 2021 | June 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17599253 | POLYMER AGENTS FOR CARDIOPULMONARY RESUSCITATION | September 2021 | March 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17598160 | IMIDAZOQUINOLINE COMPOUNDS AND PRODRUGS THEREOF | September 2021 | December 2024 | Allow | 39 | 1 | 0 | No | No |
| 17469232 | METHOD FOR LIQUID-TO-SOLID PHASE SEPARATION OF URANIUM AND URANYL CONTAMINANT FROM VARIOUS SOLUTIONS | September 2021 | March 2025 | Abandon | 42 | 2 | 1 | No | No |
| 17464256 | SURFACE DISINFECTANT WITH RESIDUAL BIOCIDAL PROPERTY | September 2021 | June 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17464268 | SURFACE DISINFECTANT WITH RESIDUAL BIOCIDAL PROPERTY | September 2021 | January 2024 | Abandon | 28 | 2 | 0 | No | No |
| 17435110 | INDUCING CASPASE ACTIVITY | August 2021 | November 2024 | Allow | 39 | 2 | 0 | No | No |
| 17400957 | COMPOSITIONS COMPRISING PGI2-RECEPTOR AGONISTS AND PROCESSES FOR THE PREPARATION THEREOF | August 2021 | July 2023 | Allow | 23 | 1 | 0 | No | No |
| 17443743 | FRAGRANCE COMPOSITION | July 2021 | April 2025 | Abandon | 45 | 4 | 1 | Yes | No |
| 17384629 | COMPOSITION AND METHOD FOR REDUCING THE INFECTIVITY AND VIRUCIDAL ACTIVITY OF SARS-COV-2 | July 2021 | August 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17378083 | CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | July 2021 | December 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17423377 | METHOD FOR ORAL CAVITY CARE | July 2021 | March 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17376237 | COMPOSITION FOR A FORMULATED ORAL PREBIOTIC EDIBLE COMPOSITION | July 2021 | September 2023 | Allow | 27 | 1 | 0 | Yes | No |
| 17366620 | EMBOLIC COMPOSITIONS | July 2021 | October 2023 | Allow | 28 | 1 | 0 | No | No |
| 17418940 | ADAMANTANECARBOXYLIC ACID BENZYL AMIDE DERIVATIVE COMPOUND AND SKIN WHITENING COMPOSITION COMPRISING SAME | June 2021 | May 2024 | Allow | 34 | 2 | 0 | Yes | No |
| 17304562 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID-LABILE DRUGS | June 2021 | June 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17356131 | KITS FOR TREATING THE HAIR | June 2021 | July 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17304494 | STABILIZED HYPOCHLOROUS ACID SOLUTION AND METHOD FOR STABILIZING HYPOCHLOROUS ACID FOR LONGER SHELF LIFE | June 2021 | July 2024 | Abandon | 37 | 2 | 0 | No | No |
| 17416309 | SOLID COSMETIC COMPOSITION CONTAINING VEGETABLE BUTTERS | June 2021 | September 2024 | Allow | 39 | 2 | 1 | No | No |
| 17342983 | METHOD FOR BOWEL PREPARATION | June 2021 | May 2023 | Allow | 23 | 1 | 0 | No | No |
| 17338982 | VIRUCIDAL COMPOSITIONS AND METHODS | June 2021 | February 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17299697 | MULTICOMPONENT IN SITU COLORATION COMPOSITION | June 2021 | January 2025 | Allow | 44 | 1 | 0 | No | No |
| 17332704 | SYNTHETIC MELANIN NANOPARTICLES AND USES THEREOF | May 2021 | May 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17317517 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | May 2021 | January 2023 | Allow | 20 | 0 | 0 | Yes | No |
| 17256979 | COMPLEX FOR ENHANCING IMMUNE RESPONSE | May 2021 | August 2024 | Allow | 43 | 1 | 0 | Yes | No |
| 17291717 | COSMETIC COMPOSITION COMPRISING A POLYHYDROXYALKANOATE IN AN OILY MEDIUM | May 2021 | November 2024 | Allow | 42 | 1 | 0 | No | No |
| 17288173 | BIOENERGETIC NICOTINIC ACID GLYCEROL ESTERS, COMPOSITIONS AND METHODS OF USING SAME | April 2021 | June 2023 | Allow | 25 | 0 | 0 | Yes | No |
| 17236848 | METHOD FOR PRODUCING A NANOSTRUCTURED COMPLEX (CFI-1), A PROTEIN-ASSOCIATED NANOSTRUCTURED COMPLEX (MRB-CFI-1) AND USE | April 2021 | November 2022 | Allow | 19 | 0 | 0 | Yes | No |
| 17236861 | METHOD FOR PRODUCING A NANOSTRUCTURED COMPLEX (CFI-1), A PROTEIN-ASSOCIATED NANOSTRUCTURED COMPLEX (MRB-CFI-1) AND USE | April 2021 | February 2023 | Allow | 22 | 0 | 0 | Yes | No |
| 17236839 | METHOD FOR PRODUCING A NANOSTRUCTURED COMPLEX (CFI-1), A PROTEIN-ASSOCIATED NANOSTRUCTURED COMPLEX (MRB-CFI-1) AND USE | April 2021 | November 2022 | Allow | 19 | 0 | 0 | Yes | No |
| 17230175 | IMMUNOSUPPRESSANT FORMULATIONS | April 2021 | April 2024 | Allow | 36 | 3 | 0 | No | No |
| 17228753 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING AMINOPYRIMIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE THEREOF | April 2021 | July 2024 | Allow | 39 | 4 | 0 | Yes | No |
| 17219915 | HYDROGEL COMPOSITION WITH THERMOS-SENSITIVE AND IONIC REVERSIBLE PROPERTIES, CARRIER, METHOD FOR PREPARING AND METHOD OF USE THEREOF | April 2021 | November 2023 | Allow | 31 | 2 | 1 | Yes | No |
| 17219253 | LEVODOPA FRACTIONATED DOSE COMPOSITION AND USE | March 2021 | May 2022 | Allow | 13 | 2 | 0 | Yes | No |
| 17256980 | METHODS FOR PREPARING COMPLEX FOR ENHANCING IMMUNE RESPONSE | March 2021 | October 2024 | Allow | 46 | 1 | 1 | No | No |
| 17206822 | Debridement Composition | March 2021 | April 2025 | Allow | 48 | 2 | 1 | No | No |
| 17203403 | PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL | March 2021 | May 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17188359 | INJECTABLE SLURRIES AND METHODS OF MANUFACTURING AND USING THE SAME | March 2021 | November 2023 | Allow | 33 | 2 | 0 | No | No |
| 17269912 | MICROCAPSULE-BASED VACCINE | February 2021 | March 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17268281 | AN OILY COMPOSITION | February 2021 | May 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17173400 | MELTING MASSAGE BAR | February 2021 | December 2023 | Allow | 34 | 4 | 0 | No | No |
| 17171060 | NOVEL NANOPARTICLES USING ANIONIC POLYMER, PREPARATION METHOD AND COMPOSITION THEREOF | February 2021 | April 2023 | Allow | 26 | 0 | 1 | Yes | No |
| 17154516 | Phenylephrine Hydrochloride Compositions and Containers | January 2021 | April 2022 | Allow | 14 | 8 | 1 | Yes | Yes |
| 17262198 | LYCOPENE COMPOSITIONS AND METHODS FOR PROTECTING SKIN AGAINST ULTRAVIOLET RADIATION | January 2021 | August 2024 | Abandon | 43 | 4 | 1 | Yes | No |
| 17151093 | Composition, Method of Making, Method of Use and System for Hair Health | January 2021 | March 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17145999 | Esterquat Compositions | January 2021 | May 2024 | Allow | 40 | 1 | 0 | No | No |
| 17145086 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | January 2021 | July 2023 | Allow | 30 | 1 | 0 | No | No |
| 17144877 | LABELED SILICA-COATED GOLD NANORODS AND A METHOD FOR PRODUCING THE SAME | January 2021 | January 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17144033 | FORMULATIONS COMPRISING CYCLOSPORIN A | January 2021 | August 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17257159 | METHOD FOR PREPARING ORGANIC-INORGANIC HYBRID MICROCAPSULE | December 2020 | January 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17254182 | PHOTOSTABILIZING COMPOUNDS, COMPOSITIONS, AND METHODS | December 2020 | August 2022 | Allow | 20 | 1 | 0 | No | No |
| 17253577 | OSCILLATORY GELS | December 2020 | July 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17123313 | FIBER CONTAINING HAIR STYLING COMPOSITION | December 2020 | December 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 17252782 | Use of Apoptotic Compensatory Proliferation Signaling Vesicles in Tissue Repair and Wound Healing | December 2020 | April 2024 | Allow | 40 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROSENTHAL, ANDREW S.
With a 24.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ROSENTHAL, ANDREW S works in Art Unit 1613 and has examined 683 patent applications in our dataset. With an allowance rate of 54.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.
Examiner ROSENTHAL, ANDREW S's allowance rate of 54.0% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ROSENTHAL, ANDREW S receive 2.43 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ROSENTHAL, ANDREW S is 28 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +45.2% benefit to allowance rate for applications examined by ROSENTHAL, ANDREW S. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 15.1% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 21.1% of cases where such amendments are filed. This entry rate is in the 19% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 60.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 48.4% of appeals filed. This is in the 10% percentile among all examiners. Of these withdrawals, 58.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 83.2% are granted (fully or in part). This grant rate is in the 93% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 54% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.